$6.44
3.38% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Kura Oncology, Inc. Stock price

$6.44
+0.64 11.03% 1M
-3.19 33.13% 6M
-2.27 26.06% YTD
-15.13 70.14% 1Y
-10.46 61.89% 5Y
-8.56 57.07% 10Y
-8.56 57.07% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.22 3.30%
ISIN
US50127T1097
Symbol
KURA
Sector
Industry

Key metrics

Market capitalization $557.54m
Enterprise Value $-91.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -1.34
P/S ratio (TTM) P/S ratio 8.20
P/B ratio (TTM) P/B ratio 1.43
Revenue (TTM) Revenue $67.99m
EBIT (operating result TTM) EBIT $-203.44m
Free Cash Flow (TTM) Free Cash Flow $110.55m
Cash position $658.19m
EPS (TTM) EPS $-2.09
P/E forward negative
P/S forward 4.03
EV/Sales forward negative
Short interest 9.67%
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Kura Oncology, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
68 68
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 82 82
42% 42%
120%
- Research and Development Expense 190 190
50% 50%
279%
-203 -203
11% 11%
-298%
- Depreciation and Amortization 0.86 0.86
1% 1%
1%
EBIT (Operating Income) EBIT -203 -203
11% 11%
-299%
Net Profit -182 -182
8% 8%
-268%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –
Neutral
GlobeNewsWire
8 days ago
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting o...
Neutral
GlobeNewsWire
12 days ago
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically mean...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today